Agendia closes $23M Series E financing

Dutch molecular cancer diagnostic company Agendia has closed $23 million in series E financing. The round was led by an undisclosed family investment firm that provided approximately half of the funds. Two independent entrepreneurs each contributed $1 million, and the rest of the capital was raised through Agendia's existing investor base.

"The success of this financing round was aided by MammaPrint's increasing U.S. demand, as well as growing reimbursement from private U.S. payors. The proceeds will be used to accelerate the commercialization of MammaPrint in the U.S. market," said Dr. Bernhard Sixt, President and CEO of Agendia. MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery.

- check out Agencia's release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.